Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Amortization of Deferred Charges (2022 - 2023)

Whitehawk Therapeutics (WHWK) has disclosed Amortization of Deferred Charges for 2 consecutive years, with -$486000.0 as the latest value for Q4 2023.

  • Quarterly Amortization of Deferred Charges rose 54.41% to -$486000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$2.3 million through Dec 2023, changed N/A year-over-year, with the annual reading at -$3.1 million for FY2023, 158.11% down from the prior year.
  • Amortization of Deferred Charges for Q4 2023 was -$486000.0 at Whitehawk Therapeutics, up from -$588000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was -$149000.0 in Q3 2022, with the low at -$1.1 million in Q4 2022.